

# THE INTERNATIONAL COMPARATIVE LEGAL GUIDE TO: PRIVATE EQUITY 2023/2024

9TH EDITION

**ICLG.com**

COMPARE & RESEARCH THE LAW, WORLDWIDE.

**Dechert**  
LLP

# Expert Analysis Chapter

1

**2023 and Beyond: Private Equity Outlook for 2024**  
Siew Kam Boon, Sarah Kupferman & Sam Whittaker, Dechert LLP

## Q&A Chapters

4

**Australia**  
MinterEllison: Kimberley Low, Michael Wallin & Nick Kipriotis

14

**Austria**  
Schindler Attorneys: Florian Philipp Cvak & Clemens Philipp Schindler

25

**Brazil**  
Mello Torres Advogados: Carlos José Rolim de Mello, Roberto Panucci & Rafael Biondi Sanchez

33

**Canada**  
McMillan LLP: Michael P. Whitcombe, Brett Stewart, Enda Wong & Bruce Chapple

42

**Cayman Islands**  
Maples Group: Julian Ashworth, Patrick Rosenfeld, Lee Davis & Stef Dimitriou

50

**China**  
Han Kun Law Offices LLP: Charles Wu & Hanpeng (Patrick) Hu

57

**France**  
Vivien & Associés AARPI: Lisa Becker, Julie Tchaglass, Marine Pelletier-Capes & Julien Koch

65

**Germany**  
Weil, Gotshal & Manges LLP: Andreas Fogel & Benjamin Rapp

73

**Hungary**  
Moore Legal Kovács: Dr. Márton Kovács, Dr. Áron Kanti & Dr. Zsigmond Tóth

83

**India**  
Shardul Amarchand Mangaldas & Co.: Iqbal Khan & Devika Menon

91

**Italy**  
Legance: Marco Gubitosi & Lorenzo De Rosa

105

**Japan**  
Tokyo International Law Office: Dai Iwasaki, Yusuke Takeuchi & Tomo Greer

113

**Korea**  
Barun Law LLC: Min Hoon Yi & Si Yoon Lee

121

**Luxembourg**  
Eversheds Sutherland (Luxembourg) S.C.S.: Holger Holle, José Pascual & Rafael Moll de Alba

130

**Mexico**  
González Calvillo, S.C.: Jorge Cervantes Trejo, Bernardo Reyes Retana Krieger, Daniel Guaida Azar & Jerónimo Ramos Arozarena

138

**Nigeria**  
Banwo & Ighodalo: Ayodele Adeyemi-Faboya, Mavis Abada & Ibiyemi Ajiboye

149

**Norway**  
Aabø-Evensen & Co: Ole Kristian Aabø-Evensen

173

**Singapore**  
Allen & Gledhill LLP: Christian Chin & Lee Kee Yeng

182

**Spain**  
Garrigues: Ferran Escayola & María Fernández-Picazo

192

**Switzerland**  
Bär & Karrer Ltd.: Dr. Christoph Neeracher & Dr. Luca Jagmetti

201

**United Kingdom**  
Dechert LLP: Mark Evans & Sam Whittaker

213

**USA**  
Dechert LLP: Allie Misner Wasserman, Dr. Markus P. Bolsinger, Soo-ah Nah & Marie Mast

## USA

Dechert LLP

Allie Misner  
WassermanDr. Markus P.  
Bolsinger

Soo-ah Nah



Marie Mast

USA

## 1 Overview

### 1.1 What are the most common types of private equity transactions in your jurisdiction? What is the current state of the market for these transactions?

U.S. private equity (“PE”) deal activity during the first half of 2023 continued to slow following the surges during 2021 and the early part of 2022. While PE firms continue to have significant levels of dry powder at their disposal, the war in Ukraine, geopolitical tensions with China, regional banking system collapses, stress in the commercial office lease market, inflation and rising interest rate levels have created a more challenging environment for M&A and injected uncertainty into the outlook for the remainder of 2023. Fundraising activity slowed meaningfully in the first half of 2023, with many investors’ portfolios already overallocated to the private markets – a direct result of the declines in the value of public stocks. In addition, risk-averse lenders have made access to debt financing difficult; and with the slowdown in PE exit activity and a lack of GP distributions, LPs have been left with less capital with which to invest in new funds. The foregoing, coupled with a limited number of high-quality assets available in the market, has made the current landscape for PE challenging.

The frothy, competitive deal environment that characterized the past several years prior to the current slowdown resulted in a continued focus on portfolio company add-ons and alternative transactions, such as carve-outs, strategic partnering transactions, minority investments, club deals, growth investments, structured equity investments, private investments in public equity (“PIPEs”) and take-private transactions. We have also seen more acquisitions of founder-owned private companies than any prior year. The changing landscape in 2023 is slowing traditional PE investing and is expected to increase hold periods, but opportunities remain for portfolio company add-ons, take-privates, co-investments and opportunistic transactions, and continuation funds and GP-led secondaries continue to attract attention. Additionally, some funds may be well-positioned to take advantage of opportunities in the current market.

### 1.2 What are the most significant factors currently encouraging or inhibiting private equity transactions in your jurisdiction?

During 2021 and the early part of 2022, M&A activity was characterized by extremely competitive auctions, which resulted in historically high selling multiples, seller-favorable terms and intense pressure on certainty and speed to closing. While dry powder is still near record levels, parties are now faced with a less attractive environment for deal-making, with high inflation,

rising interest rates and bank/financial institution uncertainty increasing the cost of borrowing, which in turn is pushing down valuations and increasing the proportion of equity-to-debt for many new deals. The continued war in Ukraine, supply chain disruptions in certain industries and persistent labor shortages have also had an impact. These factors have been shifting the market away from the seller-favorable terms that dominated the last several years, and that trend is expected to continue in the near term.

The regulatory environment continues to become more challenging for PE transactions. The U.S. Federal Trade Commission (“FTC”) and Department of Justice (“DOJ”) have increased the level of scrutiny applied to acquisitions by PE firms. In addition, recent regulatory reforms involving the Committee on Foreign Investment in the United States (“CFIUS”) have led to increased timing delays and deal uncertainty for transactions involving non-U.S. investors that might raise U.S. national security issues. In addition, the U.S. government is considering measures to review outbound investments for potential U.S. national security concerns, though the scope and timing for implementation of such measures remain unclear.

### 1.3 Are you seeing any types of investors other than traditional private equity firms executing private equity-style transactions in your jurisdiction? If so, please explain which investors, and briefly identify any significant points of difference between the deal terms offered, or approach taken, by this type of investor and that of traditional private equity firms.

Over the past several years, the concentration of capital in large, multi-strategy asset managers has increased, leading to a corresponding increase in the number of deals consummated by such managers. We expect this trend to continue, as these funds are outperforming in fundraising and may be better positioned to take advantage of opportunities in the current market.

Non-traditional PE funds such as sovereign wealth funds, pension plans and family offices continue to extend investments beyond minority positions and are increasingly serving as lead investors in transactions, which has created additional competition for traditional PE funds.

## 2 Structuring Matters

### 2.1 What are the most common acquisition structures adopted for private equity transactions in your jurisdiction?

The most common acquisition structures are mergers, equity

purchases and asset purchases in the case of private targets, and one-step and two-step mergers in the case of public targets.

Historically, most PE sponsors have prioritized control investments; however, in recent years there has been an increased focus on alternative investment structures, including structured equity.

## 2.2 What are the main drivers for these acquisition structures?

The primary drivers include tax considerations, stockholder approval, speed and certainty of closing and liability issues.

Mergers offer simple execution, particularly where the target has numerous stockholders, but buyers lack privity with the target's stockholders, and the target's board may expose itself to claims by dissatisfied stockholders. Buyers often seek separate agreements with stockholders that include continued support during the period between signing and closing, releases, indemnification and restrictive covenants. However, depending on the applicable state law, enforceability issues may arise.

Stock purchases require all target stockholders to be party to and support the transaction. These agreements avoid privity and enforcement concerns that arise in a merger but may be impractical depending on the size and character of the target's stockholder base.

Asset purchases provide favorable tax treatment for acquirors because buyers can obtain a step up in tax basis in acquired assets. See section 10. Depending on the negotiated terms, buyers also may leave behind existing liabilities of the target. However, asset purchases (especially carve-out transactions) can be difficult and time-consuming to execute. Third-party contract consents may be required, and acquired assets may be entangled with seller assets that are outside the scope of the transaction. For certain regulated businesses, permits and licenses may need to be transferred or reissued. Buyers need to carefully review the business' assets and liabilities to ensure that all necessary assets are acquired and that liabilities that flow to buyers as a matter of law are not unwittingly inherited.

## 2.3 How is the equity commonly structured in private equity transactions in your jurisdiction (including institutional, management and carried interests)?

U.S. PE returns typically arise from returns on equity investments and management fees. Equity structuring varies depending on the PE sponsor involved, the portfolio company risk profile and the IRR sought. Equity most often consists of preferred and/or common equity interests held by the PE sponsor. Often, some or each type of equity is offered to existing, or "rollover," target investors. Preferred equity can be used to set minimum returns and incentivize common or other junior security holders to drive portfolio company performance. PE funds often offer portfolio company management equity-based incentive compensation in the form of stock options, restricted stock, phantom or other synthetic equity or profits interests, each of which is subject to vesting requirements. Carried interest is typically found at the fund level and does not directly relate to the structuring of the equity investment at the portfolio company level.

The main drivers for these structures are: (i) alignment of interests among the PE sponsor and any co-investors, rollover investors and management, including targeted equity returns; (ii) tax efficiency for domestic and international fund investors and other portfolio company investors, including management; and (iii) incentivizing management.

## 2.4 If a private equity investor is taking a minority position, are there different structuring considerations?

Minority investments create financial and legal issues not often encountered in control investments. Unlike control transactions, where the PE sponsor generally has unilateral control over the portfolio company, minority investors seek to protect their investment through contractual or security-embedded rights. Minority protection rights may include negative covenants or veto rights over major business decisions, including material M&A transactions, affiliate transactions, indebtedness above certain thresholds, annual budgets and business plans, strategy, senior management hiring/firing and issuances of equity. In addition, PE sponsors will seek customary minority protections such as board and committee representation, information and inspection rights, tag-along rights, limitations on drag-along rights of the controlling party, registration rights and pre-emptive rights.

For transactions subject to CFIUS review, non-U.S. PE investors taking a minority position might be required to forego certain rights that they otherwise would seek (e.g., board representation and access to non-public information) in order to avoid triggering CFIUS review or to otherwise facilitate obtaining CFIUS clearance.

## 2.5 In relation to management equity, what is the typical range of equity allocated to the management, and what are the typical vesting and compulsory acquisition provisions?

Management equity is typically subject to time- and/or performance-based vesting. Time-based awards vest in specified increments over several years (typically four to five years (in the Eastern United States) and sometimes less (in the Western United States)), subject to the holder's continued employment. Performance-based awards vest upon achieving performance goals, often based on the PE sponsor achieving a certain IRR or multiple on invested capital upon exit, which in some instances is subject to minimum return hurdles. Time-based awards typically accelerate upon the PE sponsor's exit. Forfeiture of both vested and unvested equity in the event of a termination for cause is common.

Compulsory repurchase provisions (i.e., "put" rights) are not typical, but portfolio companies customarily reserve the right to repurchase an employee's equity in connection with the employee's termination at either fair market value or the lesser of fair market value and the original purchase price, depending on the timing and reason for termination.

The proportion of equity allocated to management (as well as the allocation among executives) varies by PE fund and the capital structure of the portfolio company, but management equity pools for portfolio companies typically range from 7.5–15% of equity on a fully diluted basis, with the higher end of that range being more typical with smaller equity investments and equity structures where the PE sponsor holds more preferred equity.

## 2.6 For what reasons is a management equity holder usually treated as a good leaver or a bad leaver in your jurisdiction?

Management equity holders are typically treated as good leavers if their employment is terminated without cause, they resign with good reason after a specified period of time, their employment terminates due to death or disability or upon normal retirement.

Bad leavers are commonly those who are terminated for cause and, in some cases, those who resign without good reason.

### 3 Governance Matters

#### 3.1 What are the typical governance arrangements for private equity portfolio companies? Are such arrangements required to be made publicly available in your jurisdiction?

PE sponsors generally form new buyer entities (most often corporations or tax pass-through entities such as limited liability companies (“LLCs”) or limited partnerships (“LPs”)) through which they complete acquisitions and maintain their ownership interest in underlying portfolio companies. Governance arrangements are typically articulated at the level in the portfolio company’s ownership structure where management investors will hold their equity interests post-acquisition. For control investments, PE sponsors will often control the manager and/or the board of the buyer, any parent companies above the buyer entity, and the portfolio company.

Governance agreements among PE sponsors, co-investors and management will most commonly be in the form of a shareholders’ agreement, LLC agreement or LP agreement, depending on the form of the entity. These agreements ordinarily contain, among other things: (i) transfer restrictions; (ii) tag-along and drag-along rights; (iii) pre-emptive rights; (iv) rights to elect the manager or board of directors; (v) information rights; (vi) special rights with respect to management equity, including repurchase rights; and (vii) limits on certain fiduciary and other duties to the extent permitted by state law. For larger portfolio companies contemplating exits through initial public offerings (“IPOs”), registration rights may also be sought. Governance arrangements are not generally required to be made publicly available unless the portfolio company is a public reporting company. Charters are required to be filed with the state of organization but generally do not include meaningful governance provisions.

Beginning in 2024, the Corporate Transparency Act will require most U.S. companies (subject to certain exceptions) to begin reporting to FinCEN certain information about their beneficial owners (defined as any individual who directly or indirectly exercises substantial control over or owns or controls at least 25% of the company) and the individual who files the document forming or registering the company. Companies and their advisors should begin to prepare for the new reporting requirements now in order to avoid any potential delays in entity formation and reporting next year.

#### 3.2 Do private equity investors and/or their director nominees typically enjoy veto rights over major corporate actions (such as acquisitions and disposals, business plans, related party transactions, etc.)? If a private equity investor takes a minority position, what veto rights would they typically enjoy?

For control investments, PE sponsors will often control the portfolio company through their right to appoint the manager or a majority of the directors. As a result, major corporate actions are ultimately indirectly controlled by the PE sponsor. If a PE sponsor takes a minority position, veto rights will generally not be included in underlying governance arrangements unless the sponsor owns a substantial minority position. See question 2.4.

#### 3.3 Are there any limitations on the effectiveness of veto arrangements: (i) at the shareholder level; and (ii) at the director nominee level? If so, how are these typically addressed?

Veto rights are typically in the form of contractual rights in favor of specified shareholders or classes of equity contained in an organization’s governing documents (i.e., shareholders’ agreement, LLC agreement or LP agreement, if applicable), and are generally enforceable. For corporations, although less common, negative covenants can also be included in the charter, which would render any action taken in violation of one of those restrictions *ultra vires*. Director-level veto rights are less common, as veto rights exercised by directors will generally be subject to their overriding fiduciary duty owed to the portfolio company, unless such duties have been validly disclaimed. See question 3.4.

#### 3.4 Are there any duties owed by a private equity investor to minority shareholders such as management shareholders (or *vice versa*)? If so, how are these typically addressed?

Whether a PE investor owes duties to minority shareholders requires careful analysis and will depend upon several factors, including the legal form of the entity involved and its jurisdiction of formation.

Several jurisdictions hold that all shareholders in closely held companies owe fiduciary duties to each other and the company. In other jurisdictions, such as Delaware, only controlling shareholders owe fiduciary duties. In this context, the ability to exercise dominion and control over the corporate conduct in question (even if the controller owns less than 50% of the equity) is determinative.

Delaware is frequently chosen as the state of organization in PE transactions due to its well-developed business law and sophisticated judiciary. Under Delaware law, the primary fiduciary duties owed by a controlling shareholder (and the board of directors) to shareholders are the duties of care and loyalty (along with ancillary duties, such as those arising under the corporate opportunity doctrine). The duty of care requires directors to make informed and deliberate business decisions. The duty of loyalty requires that decisions be made in the best interests of the company and its shareholders (and not based on personal interests or self-dealing).

Under Delaware law, corporate entities can (and usually do) exculpate breaches of the duty of care; but the duty of loyalty cannot be waived in corporate organizational documents. However, the Delaware Court of Chancery recently held that shareholders can contractually waive the duty of loyalty under certain conditions concerning the sophistication of the shareholders and their ability to negotiate the waiver, the reasonableness and application of the waiver, and the clarity of the waiver language.

By contrast with the corporate statute, the Delaware statutes for alternative entities like LLCs and LPs allow the parties to broadly waive the duty of loyalty. For this reason, among others, PE sponsors frequently organize their investment vehicles as LLCs or LPs in Delaware and include in the LLC or LP agreement an express waiver of fiduciary duties owed to minority investors. Absent an express waiver, however, courts will apply traditional corporate-like fiduciary duties to the board and the controller’s conduct. In addition, shareholders’, LLC and LP agreements often include express acknowledgments that the PE sponsor actively engages in investing and has no obligation to share information or opportunities with the portfolio company. These agreements also typically provide that the

portfolio company (and not PE sources) serve as the first source of indemnification for claims against PE sponsor employees serving on the portfolio company's board.

**3.5 Are there any limitations or restrictions on the contents or enforceability of shareholder agreements (including (i) governing law and jurisdiction, and (ii) non-compete and non-solicit provisions)?**

Shareholders', LLC and LP agreements are generally governed by and must be consistent with the laws of the state of the entity's formation. LLC and LP agreements, which are contracts among a limited liability company or limited partnership and its members or partners, as applicable, provide greater flexibility than shareholders' agreements, which are contracts that are typically among a corporation and its shareholders. Although governing law and submission to jurisdiction provisions may refer to the law of other states or may apply the law of two or more states through bifurcation provisions, this approach is unusual and should be avoided, as it is unduly complicated and references to state laws outside the state of formation may render certain provisions unenforceable.

Non-competition and non-solicitation provisions in shareholders', LLC and LP agreements generally restrict management and non-PE co-investors, but not PE investors. These provisions are subject to the same enforceability limitations as when contained in other agreements. Enforceability will be governed by state law, which varies significantly by jurisdiction and continues to evolve, and must be evaluated on a case-by-case basis. At a minimum, such covenants must protect the legitimate business interests of the company and be reasonable with respect to duration, geographic reach, and scope of restricted activities. Unreasonable temporal and/or geographic scope may render provisions unenforceable or subject to unilateral modification by courts. Other contractual provisions such as transfer restrictions, particularly for corporate entities, may be subject to public policy limitations in certain jurisdictions.

**3.6 Are there any legal restrictions or other requirements that a private equity investor should be aware of in appointing its nominees to boards of portfolio companies? What are the key potential risks and liabilities for (i) directors nominated by private equity investors to portfolio company boards, and (ii) private equity investors that nominate directors to boards of portfolio companies?**

There are no meaningful legal restrictions applicable to PE investors who nominate directors to private company boards, other than restrictions under applicable antitrust laws. For example, the Clayton Act generally prohibits a person from serving as an officer or director of two competing corporations. In 2019, the U.S. Department of Justice ("DOJ") expressed a desire to extend the scope of these restrictions on interlocking directorships to non-corporate entities and entities that appoint directors to competing entities as representatives or "deputies" of the same investor. If the Clayton Act is expanded in such a manner, PE funds may need to reevaluate their existing corporate governance arrangements with their portfolio companies. In 2022, DOJ officials said they were "ramping up efforts" to identify interlocking director violations and "committed to taking aggressive action" against PE investments in competitors that lead to interlocking boards. DOJ enforcement actions in 2022 and 2023 resulted in resignations of board members who were designees of PE firms, including Apollo and Thoma Bravo.

PE investors should also be aware that some U.S. states have been enacting gender diversity requirements for the boards of

companies organized and/or headquartered in the applicable state, and NASDAQ has enacted listing rules regarding board diversity and related disclosure.

Potential risks and liabilities exist for PE-sponsored directors nominated to boards. Directors appointed by PE investors should be aware that they owe fiduciary duties in their capacity as directors (subject to certain exceptions in the case of an LLC or LP where fiduciary duties of directors are permitted to be, and have been, expressly disclaimed). Directors of corporations cannot delegate their decision-making responsibility to or defer to the wishes of a controlling shareholder, including their PE sponsor. In addition, conflicts of interest may arise between the PE firm and the portfolio company. Directors should be aware that they owe a duty of loyalty to the company for the benefit of all of its shareholders (absent a waiver under the circumstances discussed above) and that conflicts of interest create exposure for breach of duty claims. Furthermore, while the fiduciary duties to the company remain the same, the ultimate stakeholders may change in certain jurisdictions when a company is insolvent or in the zone of insolvency – in such situations, directors may also owe fiduciary duties to certain creditors of the portfolio company.

**3.7 How do directors nominated by private equity investors deal with actual and potential conflicts of interest arising from (i) their relationship with the party nominating them, and (ii) positions as directors of other portfolio companies?**

See question 3.4. Under the duty of loyalty, directors must act in good faith and in a manner reasonably believed to be in the best interests of the portfolio company and may not engage in acts of self-dealing. In addition, directors appointed by PE firms who are also officers of the PE firm itself owe potentially conflicting fiduciary duties to PE fund investors. Directors need to be cognizant of these potential conflicts and seek the advice of counsel.

## 4 Transaction Terms: General

**4.1 What are the major issues impacting the timetable for transactions in your jurisdiction, including antitrust, foreign direct investment and other regulatory approval requirements, disclosure obligations and financing issues?**

The timetable for a transaction generally depends on the due diligence process, negotiation of definitive documentation, and obtaining debt financing, third-party consents and regulatory approvals, if applicable.

Antitrust clearance is the most common regulatory clearance faced. Only persons and entities that meet regulatory thresholds are required to make filings under the Hart-Scott-Rodino Act ("HSR"). The most significant threshold in determining reportability is the minimum size of transaction threshold (2023: US\$11.4 million). In most transactions, the HSR filing is submitted after the parties have signed a definitive purchase agreement. Once both parties have filed, they must observe a statutory waiting period, which typically lasts 30 days (15 days for certain transactions) and must be observed before the transaction can close. Parties can expedite review by filing based on executed letters of intent or, historically, by requesting early termination of the waiting period; however, the FTC and the DOJ issued a suspension of early terminations in early 2021 that was still in effect at the end of Q2 2023.

Transactions raising anticompetitive concerns may receive a “second request” from the reviewing agency, resulting in a significantly more extended review period. Recently, the FTC and DOJ have increased their review of PE-led deals and signaled that PE funds and their roll-up strategies will face greater scrutiny. For example, in 2022, the FTC brought two enforcement actions against PE firm JAB Consumer Products for its acquisitions of SAGE Veterinary Partners and Ethos Veterinary Health. Both firms were competitors of JAB’s portfolio companies in the same industry. The consent agreements require JAB to divest competing specialty and emergency pet clinics in local markets. At the same time, the FTC is also requiring JAB to obtain prior approval before it can acquire any specialty or emergency veterinary clinics in certain areas for over 10 years.

The FTC and DOJ have also increased their focus on acquisition transactions, releasing two proposed enforcement objectives in the last few months. On June 27, 2023, the FTC, with the concurrence of the DOJ, announced proposed rules that, once implemented, will significantly increase the amount of information that transaction parties will need to include in their HSR filings. After the proposed new rules are implemented, it is expected that the estimated average preparation time for completing HSR filings will extend well beyond the typical five to 10 business days following the execution of a purchase agreement, potentially delaying closings. Among the proposed changes affecting private equity firms, limited partners that hold a 5% or greater interest in a partnership would be required to be disclosed in HSR filings (in addition to general partners, who are currently required to be disclosed for partnerships).

On July 19, 2023, the DOJ and FTC announced new draft Merger Guidelines, which are subject to public comment for 60 days. The draft Merger Guidelines are intended to increase merger enforcement, including enforcement against serial or roll-up acquisitions. The draft Merger Guidelines identify concerns with “a firm that engages in an anticompetitive pattern or strategy of multiple small acquisitions in the same or related business lines” even if no single acquisition would violate the antitrust laws. The agencies are concerned that “a cumulative series of mergers” may substantially lessen competition or tend to create a monopoly.

In addition, parties to transactions potentially affecting national security may seek regulatory clearance from CFIUS. Given recent political developments, regulatory changes, and increased resources available to CFIUS, buyers should expect enhanced scrutiny by the U.S. government of certain foreign investments in the United States, particularly in the technology and defense-related industries. Recent CFIUS reforms that have been implemented pursuant to the Foreign Investment Risk Review Modernization Act of 2018 (“FIRRMA”) have expanded CFIUS’ powers and also now require mandatory submissions to CFIUS for certain types of transactions that are more likely to raise U.S. national security concerns (previously, CFIUS was typically a voluntary process). Prudent buyers seek CFIUS approval to forestall forced divestiture orders.

The Biden Administration as well as the U.S. Congress are considering measures to review outbound investments from the United States for national security concerns. These potential measures are largely driven by concerns related to U.S. capital flowing into sectors of the Chinese economy that support the Chinese government’s “military-civil fusion” regime, which seeks to develop the most technologically advanced military by removing barriers between civilian and defense sectors. As a result, the measures will likely target investments in Chinese sectors such as artificial intelligence, semiconductors, and quantum computing and/or involving military and dual-use technologies. The first phase of an outbound investment review

mechanism will likely center around requiring notifications to the U.S. government for investments in the applicable sectors of the Chinese economy as a means for the U.S. government to collect information about such activities. At this time, the U.S. government is unlikely to impose a “reverse CFIUS” process that requires investors to seek U.S. government approval for in-scope outbound investments, though such a requirement could materialize in the future. The U.S. government was expected to announce relevant measures in early 2023, but that announcement was pushed back and the timing is now unclear, although we anticipate seeing movement in this area in late 2023.

Other contractual or government approvals relating to specific sectors or industries (e.g., the Jones Act or FCC approval) may also be necessary or prudent depending on the nature of the business being acquired or the importance of underlying contracts.

#### 4.2 Have there been any discernible trends in transaction terms over recent years?

For years, competitive auctions have been the preferred method for exits by PE sponsors and other sellers in the United States. As a result of these competitive auctions, the scarcity of viable targets and the abundant availability of equity financing and debt financing prior to 2022, transaction terms shifted strongly in favor of sellers, including the limiting of conditionality and post-closing indemnification obligations. Transactions have commonly been consummated with public-style closing conditions (i.e., representations subject to MAE bring-down), financing conditions have disappeared, and reverse break fees are common. The use of representations and warranties (“R&W”) insurance has been implemented across transactions of all sizes and is now used equally by PE and strategic buyers. Transactions are being structured more frequently as walk-away deals, with the R&W insurance carrier being responsible for most breaches of representations between the retention (which refers to the self-insured deductible) and insured limit under the policy. It also is becoming more common to include terms regarding CFIUS in transactions involving non-U.S. investors.

Starting in the second half of 2022, with the market for M&A softening and there being an increase in proprietary deals and auctions with a lack of interested bidders, there has been a noticeable shift to more buyer-friendly terms, including lower purchase prices, extended exclusivity periods and use of earn-outs being used to offset upfront cost at closing and to bridge the valuation gap. Given the increasing cost of debt, rising inflation and the volatility of the market, we expect to see these trends continue for the foreseeable future.

## 5 Transaction Terms: Public Acquisitions

#### 5.1 What particular features and/or challenges apply to private equity investors involved in public-to-private transactions (and their financing) and how are these commonly dealt with?

Public company acquisitions pose a number of challenges for PE sponsors. The merger proxy or tender offer documents provided to target shareholders will include extensive disclosure about the transaction, including the buyer and its financing, and a detailed background section summarizing the sale process and negotiations. These disclosure requirements are enhanced if the Rule 13e-3 “going private” regime applies to the transaction.

A public company acquisition will require either consummation of a tender offer combined with a back-end merger or

target shareholder approval at a special shareholder meeting. In either case, there will be a significant delay between signing and closing that must be reflected in sponsor financing commitments, with a minimum of six weeks for a tender offer (which must remain open for 20 business days) and two to three months for a merger that requires a special meeting.

Absent unusual circumstances, there will be no ability to seek indemnification or other recourse for breaches of target representations or covenants, but R&W insurance may be obtained. Public company transactions also present unique challenges for the use of creative financing methods such as earn-outs, contingent value rights and seller financing.

### 5.2 What deal protections are available to private equity investors in your jurisdiction in relation to public acquisitions?

Generally, the acquisition of a U.S. public company is subject to the ability of the target's board to exercise a "fiduciary out" to pursue superior offers from third parties until the deal is approved by the target shareholders or a tender offer is consummated. A PE buyer typically negotiates an array of "no shop" protections that restrict the target from actively soliciting competing bids, along with matching and information rights if a third-party bid arises. If a target board exercises its fiduciary out to terminate an agreement and enter into an agreement with an unsolicited bidder, or changes its recommendation of the deal to shareholders, break-up fees are customary. Fees typically range from 3–4%.

## 6 Transaction Terms: Private Acquisitions

### 6.1 What consideration structures are typically preferred by private equity investors (i) on the sell-side, and (ii) on the buy-side, in your jurisdiction?

U.S. PE buyers typically purchase companies on a cash-free, debt-free basis. U.S. transactions typically involve a working capital adjustment (as opposed to a locked-box approach) where the parties agree to a target amount that reflects a normalized level of working capital for the business (often a trailing six- or 12-month average) and adjust the purchase price post-closing to reflect any overage or underage of working capital actually delivered at closing. Depending on the nature of the business being acquired and the dynamics of the negotiations, the price may also include earn-outs or other contingent payments that provide creative solutions to disagreements over the target's valuation. Over the last year, the challenging market conditions and the resulting valuation gaps have paved the way for a rise in earn-outs and other deferred consideration in transaction agreements.

### 6.2 What is the typical package of warranties / indemnities offered by (i) a private equity seller, and (ii) the management team to a buyer?

With the prevalence of R&W insurance, post-closing indemnification by sellers, which was once intensely negotiated, has become less important for allocating risk between buyers and sellers. Historically, sellers would indemnify buyers for breaches of representations and warranties, breaches of covenants and pre-closing tax liabilities, and the parties would carefully negotiate a series of limitations and exceptions to the indemnification. When buyers obtain R&W insurance, sellers typically provide only limited indemnification, if any, for a portion of the

retention under the policy (e.g., 50% of a retention equal to 1% (or less) of enterprise value). Public-style walk-away deals where sellers provide no indemnification have become common, and proposing a walk-away deal may effectively be required for buyers in competitive auctions.

For issues identified during due diligence, buyers may negotiate for special indemnities, with the terms depending on the nature and extent of the exposure and the parties' relative negotiating power.

Management team members typically do not provide any special indemnification to buyers in their capacity as management.

### 6.3 What is the typical scope of other covenants, undertakings and indemnities provided by a private equity seller and its management team to a buyer?

Historically, U.S. PE sellers typically have not agreed to non-competition covenants, and restrictive covenants were limited to employee non-solicitation covenants. Conversely, selling management investors and certain co-investors typically agree to non-competition and other restrictive covenants. In recent years, limited non-competition covenants by PE sellers have become somewhat more common given the high valuations paid by buyers. However, these covenants, if present, are typically very narrow and may be limited to restrictions on purchasing enumerated target companies. Restrictive covenants by PE sellers tend to be intensely negotiated, and the terms, including the length of the restrictions, any exceptions and their applicability to PE fund affiliates, depend on the parties' negotiating strength and the nature of the PE seller (including fiduciary duties owed to its LPs) and the business being sold.

Counsel should ensure that key members of the target's management team continue to be bound by existing restrictive covenants. The scope of permissible non-competition and other restrictive covenants varies significantly from state to state, and, in recent years, many courts have increased the level of scrutiny that they apply to such covenants. At a minimum, restrictive covenants must not be broader than necessary to protect the legitimate business interests of the company and be reasonable with respect to duration, geographic reach, and scope of restricted activities. Covenants that are overbroad face a risk of being unilaterally narrowed by a court or, as has become increasingly common over the last several years, declared unenforceable in their entirety. See question 11.1 for a discussion of the New York State Legislature's recent bill banning new employee non-competes and the FTC's proposed rules prohibiting employee non-competes.

### 6.4 To what extent is representation & warranty insurance used in your jurisdiction? If so, what are the typical (i) excesses / policy limits, and (ii) carve-outs / exclusions from such insurance policies, and what is the typical cost of such insurance?

PE and other sophisticated sellers routinely request that recourse be limited to R&W insurance obtained by buyers.

Policy terms commonly include coverage limits of 5–10% of target enterprise value, a 0.75–1% retention (stepping down to 0.5% after one year), six years of coverage for breaches of fundamental representations and three years of coverage for breaches of other representations. Exclusions include issues identified during due diligence, certain liabilities known to the buyer, benefit plan underfunding and certain environmental liabilities, and may also include industry and deal-specific exclusions based on areas of concern arising during the underwriting process. In

addition, exclusions have been expanded over the last few years to include liabilities related to PPP loans.

Despite competition among R&W insurers, consistent with other insurance markets, pricing of R&W insurance policies has relaxed slightly, with premiums and broker fees commonly around 3–4% of the policy limit, and underwriting due diligence fees of US\$30,000–US\$50,000. In addition, the premium is subject to taxation under state law.

#### 6.5 What limitations will typically apply to the liability of a private equity seller and management team under warranties, covenants, indemnities and undertakings?

For transactions with indemnification, representations and warranties typically survive for 12–24 months post-closing, with 12 months being most common, although certain specified representations may survive longer. For example, tax, employee benefit and fundamental representations often survive for several years or until expiration of the applicable statute of limitations. Fundamental representations typically include due organization, enforceability, ownership/capitalization, subsidiaries and brokers and may also include affiliate transactions. For walk-away R&W insurance transactions, representations and warranties typically do not survive the closing.

For transactions without R&W insurance, indemnification caps typically range from 5–20% of the purchase price, whereas a significantly lower cap (e.g., 0.5% or an amount to cover the retention) is typically negotiated when the buyer is obtaining R&W insurance but the parties have not agreed to a full walk-away deal. Liability for breaches of fundamental representations, breaches of covenants and fraud is often uncapped or capped at the purchase price. Although dollar-one thresholds are sometimes used, sellers will often only be responsible for damages above a deductible amount.

#### 6.6 Do (i) private equity sellers provide security (e.g., escrow accounts) for any warranties / liabilities, and (ii) private equity buyers insist on any security for warranties / liabilities (including any obtained from the management team)?

With the prevalence of R&W insurance across the market, escrows and holdbacks to cover indemnification for representation breaches are less common. However, for transactions with R&W insurance that are not walk-away deals, sellers generally place 50% of the retention under the R&W insurance policy in escrow. Escrows for post-closing purchase price adjustments remain common, as do special escrows to address issues identified during due diligence.

#### 6.7 How do private equity buyers typically provide comfort as to the availability of (i) debt finance, and (ii) equity finance? What rights of enforcement do sellers typically obtain in the absence of compliance by the buyer (e.g., equity underwrite of debt funding, right to specific performance of obligations under an equity commitment letter, damages, etc.)?

U.S. PE buyers typically fund acquisitions through a combination of equity and third-party debt financing. The PE sponsor will deliver an equity commitment letter to the buyer under which it agrees to fund a specified amount of equity at closing, and the seller will generally be named a third-party beneficiary. In a club deal, each PE sponsor may deliver its own equity commitment letter.

Committed lenders will deliver debt commitment letters to the buyer. Often, PE buyers and their committed lenders will limit sellers' rights to specifically enforce the debt commitment. See question 6.8.

#### 6.8 Are reverse break fees prevalent in private equity transactions to limit private equity buyers' exposure? If so, what terms are typical?

In the current market, closings are rarely, if ever, conditioned on the availability of a buyer's financing. In certain circumstances, PE buyers may accept the risk that they could be forced to close the transaction by funding the full purchase price with equity. However, buyers seeking to limit such exposure typically negotiate for a reverse break fee, which allows termination of the transaction in exchange for payment of a pre-determined fee if certain conditions are satisfied. Depending on the terms, reverse break fees may also be triggered under other circumstances, such as a failure to obtain HSR approval. Reverse break fees can vary from 3–10% of the target's enterprise value, with the typical fee in the range of 5–7% of enterprise value, and may be tiered based on different triggering events. Where triggered, reverse break fees typically serve as a seller's sole and exclusive remedy against a buyer. Given that PE buyers typically have no assets prior to equity funding at closing, sellers commonly require PE sponsors to provide limited guarantees of reverse break fees.

## 7 Transaction Terms: IPOs

#### 7.1 What particular features and/or challenges should a private equity seller be aware of in considering an IPO exit?

Exits through IPOs will often be at higher multiples and more readily apparent market prices than exits through third-party sale transactions. However, exits through IPOs come with the cost and compliance burden of the federal disclosure rules and are subject to volatile market conditions. In 2022 through the first half of 2023, PE exits via IPO have been almost non-existent. Going public through an acquisition by a special purpose acquisition company ("SPAC") (i.e., a de-SPAC transaction) has decreased in popularity recently, given heightened regulatory scrutiny, the performance of recent de-SPAC transactions, increased litigation, decreased public company valuations and general uncertainty in the public markets.

Unlike third-party sales, PE sponsors continue to own significant amounts of portfolio companies' equity following an IPO or de-SPAC transaction. As a result, PE sponsors' ownership interests and rights and the nature of any affiliate transactions with portfolio companies will be subject to public disclosure and scrutiny. PE sponsor management and monitoring agreements commonly terminate in connection with IPOs.

Seeking to retain control over their post-IPO stake and ultimate exit, PE sponsors often obtain registration rights and adopt favorable bylaw and charter provisions, including board nomination rights, permitted stockholder action by written consent and rights to call special stockholder meetings. Because many U.S. public companies elect board members by plurality vote, PE sponsors often retain the right to nominate specific numbers of directors standing for re-election following the IPO. Absent submission of nominees by third-party stockholders through proxy contests, which tend to ebb and flow but are generally unusual in the United States, PE sponsors can ensure election of their nominees. As these favorable PE rights are unusual in U.S. public companies, the rights often expire when the sponsor's ownership falls below specified thresholds.

Unlike private companies, most U.S. public companies are subject to governance requirements under stock exchange rules such as independent director requirements.

### 7.2 What customary lock-ups would be imposed on private equity sellers on an IPO exit?

The underwriters in an IPO typically require PE sellers to enter into lock-up agreements that prohibit sales, pledges, hedges, etc. of shares for 180 days following the IPO. After the expiration of the lock-up period, PE sponsors will continue to be subject to legal limitations on the sale of unregistered shares, including limitations on the timing, volume and manner of sale, and in club deals they may remain subject to coordination obligations with other sponsors.

### 7.3 Do private equity sellers generally pursue a dual-track exit process? If so, (i) how late in the process are private equity sellers continuing to run the dual-track, and (ii) were more dual-track deals ultimately realised through a sale or IPO?

Depending on market conditions, PE sponsors may simultaneously pursue exit transactions through IPOs and private auction sales. Dual-track transactions can help maximize the price obtained by sellers (through higher IPO multiples or increased pricing pressure on buyers), lead to more favorable transaction terms and provide sellers with greater execution certainty. The path pursued will depend on the particular circumstances of the process, but ultimate exits through private auction sales remain the most common, particularly as decreased public company valuations and an almost paralyzed IPO market have made IPOs (including de-SPAC transactions) significantly less attractive.

Dual-track strategies have historically depended on the size of the portfolio company and attendant market conditions. Dual-track approaches are less likely for small- to mid-size portfolio companies, where equity values may be insufficient to warrant an IPO. In addition, such companies are less likely to have sufficient resources to concurrently prepare for both an IPO and third-party exit. As volatility in IPO markets increases, PE firms generally focus more on sales through private auctions, where closing certainty and predictable exit multiples are more likely.

## 8 Financing

### 8.1 Please outline the most common sources of debt finance used to fund private equity transactions in your jurisdiction and provide an overview of the current state of the finance market in your jurisdiction for such debt (including the syndicated loan market, private credit market and the high-yield bond market).

The most common sources of debt financing used to fund PE transactions are loans and high-yield bonds. Loans can be provided by traditional, regulated banks or direct lenders, such as alternative asset managers and BDCs, and may be syndicated among a large group of lenders or provided by a single lender or a smaller group of lenders through a club deal. Middle market PE sponsors typically look to the loan market to fund their PE transactions, and larger PE sponsors typically look to both the loan and high-yield bond markets to fund their large-cap deals.

Due to a number of macroeconomic and geopolitical challenges, including interest rate hikes and inflation, PE deal activity remains significantly down from 2021. The syndicated

loan market and the high-yield bond market have been heavily impacted by these market conditions and have seen a significant decrease in deal activity. On the other hand, while still at a lower activity level than previous years, the private credit market led by direct lenders has remained relatively active compared to the syndicated loan and high-yield bond markets. Direct lenders continue to be the key players in PE transactions due to their competitive advantage over traditional regulated banks, including an ability to take on higher leverage, unconstrained by bank regulations, and provide faster deal execution and certainty of terms with no “market flex” risk. More direct lenders are now also equipped to fund large-cap PE transactions whereas, in the past, direct lenders typically only participated in smaller middle market deals. As market participants look for more efficient and creative ways to get deals done in a challenging economy, PE sponsors have also been utilizing seller notes and preferred equity financing to fund their acquisitions.

### 8.2 Are there any relevant legal requirements or restrictions impacting the nature or structure of the debt financing (or any particular type of debt financing) of private equity transactions?

Traditional banks continue to be governed by capital requirement guidelines and regulations affecting highly leveraged loans, including the Dodd-Frank Act. Some of these regulations were loosened in recent years in an effort to infuse capital and support the market during the COVID-19 pandemic. It remains to be seen whether similar guidelines and/or regulations will be imposed on direct lenders, as their role in the debt-financing market continues to increase, and whether a new, more restrictive regulatory scheme will be introduced or implemented with respect to traditional banks in light of the recent regional bank failures and bail-outs (including Silicon Valley Bank and others).

### 8.3 What recent trends have there been in the debt-financing market in your jurisdiction?

As fewer PE deals have been carried out, the PE financing market has also remained relatively slow throughout 2022 and the first half of 2023. In addition, due to higher pricing, most portfolio companies have refrained from refinancing their existing debt facilities, which has also contributed to the low level of activity in the PE financing market.

However, private credit funds have continued to actively raise capital, accumulating more “dry powder” to be deployed in the PE market, and direct lenders have continued to play an active role in PE financing transactions. In addition, the debt-financing market has seen a high volume of add-on acquisitions, as portfolio companies are still able to tap into existing revolver or delayed draw term loan facilities to fund those acquisitions, as well as “amend and extend” transactions as portfolio companies seek to extend the maturity of existing debt instead of refinancing it. In addition, nearing the cessation of LIBOR on June 30, 2023, the debt-financing market saw a high volume of amendments to existing debt facilities to convert LIBOR loans into SOFR loans.

## 9 Alternative Liquidity Solutions

### 9.1 How prevalent is the use of continuation fund vehicles or GP-led secondary transactions as a deal type in your jurisdiction?

As a result of declines in exit activity, there has been significant growth in the use of continuation funds and GP-led secondaries

since 2020. With a scarcity of available investments and interested buyers, GPs use continuation funds to retain investments from a previous fund that the firm is not yet ready to sell, either because the asset is underperforming or, conversely, because it is performing well. Rolling these investments over to a new fund allows PE firms to release their LPs from commitments while also giving those who are interested in continuing the investment the opportunity to roll over into the new structure alongside new investors. Global secondary transaction volume increased from \$60 billion in 2020 to around \$134 billion in 2021 and \$111 billion in 2022. We expect this trend to continue during 2023, as exit activity remains slow.

### 9.2 Are there any particular legal requirements or restrictions impacting their use?

Conflicts of interest are a major focal point for GPs when establishing a continuation fund because the PE sponsor is on both sides of the transaction. These conflicts can be managed by obtaining the requisite LP consents and keeping LPs informed and involved in the process. The PE sponsor needs to be able to articulate a compelling reason for establishing the fund and engaging in the transaction as well as justify the selling price as reasonable. This requires the GP to balance the obvious need to be profitable with the GPs fiduciary duties to its investors. Disclosure, communication and transparency are of the utmost importance. The Institutional Limited Partners Association has provided guidance on best practices for successful continuation fund transactions and recommends that a fund's investment advisory committee be involved as early as possible. PE sponsors also seek independent valuations of assets and formal fairness opinions from separate independent auditors as a way to alleviate any pricing concerns and demonstrate fairness to the sponsor's LPs. Fund organizational documents are also more commonly establishing requirements that should be met for creation of continuation funds so that fewer questions regarding the business purpose of such a transaction arise.

## 10 Tax Matters

### 10.1 What are the key tax considerations for private equity investors and transactions in your jurisdiction? Are off-shore structures common?

For non-U.S. investors, considerations include structuring the fund and investments in a manner that prevents investors from having direct exposure to U.S. net income taxes (and filing obligations) and minimizes U.S. tax on dispositions or other events (e.g., withholding taxes). Holding companies ("blockers") are often used and, in some cases, domestic statutory exceptions or tax treaties may shield non-U.S. investors from direct exposure to U.S. taxes.

For U.S. investors, considerations include minimizing a "double tax" on the income or gains and, in the case of non-corporate U.S. investors, qualifying for reduced tax rates or exemptions on certain dividend and long-term gains.

There is also a focus in transactions on maximizing tax basis in assets and deductibility of costs, expenses and interest on borrowings, as well as state and local income tax planning.

### 10.2 What are the key tax-efficient arrangements that are typically considered by management teams in private equity acquisitions (such as growth shares, incentive shares, deferred / vesting arrangements)?

Tax-efficient arrangements depend on portfolio company tax classification. For partnerships (including LLCs taxed as

partnerships), profits interests can provide meaningful tax efficiencies for management. Profits interests are granted for no consideration, entitle holders to participate only in company appreciation (not capital) and provide holders with the possibility of reduced tax rates on long-term capital gains, but they do have certain complexities not present in alternative structures. Other types of economically similar arrangements (non-ISO stock options, restricted stock units and phantom equity) do not generally allow for this same capital gain treatment.

Profits interests are not available for corporations. In certain cases, the use of restricted stock that is subject to future vesting (together with the filing of an 83(b) election) can enable a holder – under the current tax regime – to benefit from reduced tax rates on long-term capital gains.

### 10.3 What are the key tax considerations for management teams that are selling and/or rolling over part of their investment into a new acquisition structure?

Management investors selling their investment focus on qualifying for preferential tax rates or tax deferrals on income.

Management investors rolling part of their investment seek to roll in a tax-deferred manner, which may be available depending on the nature of the transaction and management's investment. In some cases (such as phantom or restricted stock unit plans), tax deferral is not achievable or may introduce significant complexity.

### 10.4 Have there been any significant changes in tax legislation or the practices of tax authorities (including in relation to tax rulings or clearances) impacting private equity investors, management teams or private equity transactions and are any anticipated?

There have been a number of significant changes in recent years. There have been changes to the tax audit process, and tax reform enacted in 2017 resulted in many material changes to the U.S. income tax system that continue to remain in effect. A series of legislative and non-legislative tax changes were made to the tax laws related to deductions for interest expense, use of carrybacks, deductions for the expense of certain types of property, and payroll taxes in response to the COVID-19 pandemic. In some cases, those rules were temporary in nature and their continuing impact should therefore be reviewed on a case-by-case basis.

More recently, a new corporate alternative minimum tax was enacted, imposing a 15% minimum tax on the adjusted financial statement income of large corporations (generally, applying to corporations with an average annual financial statement income of more than \$1 billion) for taxable years beginning after December 31, 2022, and a new 1% corporate excise tax was enacted that applies to stock repurchases by publicly traded companies after December 31, 2022. In addition, significant additional funding of the U.S. Internal Revenue Service has been included in recent government budget proposals, including for increased enforcement for complex partnerships and large corporations.

Careful consideration and attention should be given to developments in this area. Future tax legislation and other initiatives could result in additional meaningful changes to the U.S. income tax system.

## 11 Legal and Regulatory Matters

### 11.1 Have there been any significant legal and/or regulatory developments over recent years impacting private equity investors or transactions and are any anticipated?

The Tax Cuts and Jobs Act was enacted in 2017, there were legislative and other tax initiatives related to the COVID-19 pandemic, and more recent tax legislation went into effect after December 31, 2022. See section 10.

The Chair of the FTC and the Assistant Attorney General for DOJ's Antitrust Division have recently expressed concerns that certain types of PE transactions, including roll-up transactions, may harm consumers, workers, and marginalized communities. Antitrust officials have also identified PE acquisitions in the health care industry as particularly troublesome, as PE firms may be "focused on short-term gains and aggressive cost-cutting" that "can lead to disastrous patient outcomes and, depending on the facts, may create competition concerns." These concerns may lead to extended investigations, stronger consent agreements, or blocked deals. Stronger consent agreements include requiring PE firms to obtain prior approval before acquiring additional entities in the same market for 10 years.

The California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act ("CCPA"), went into effect on January 1, 2023. The law now protects personal information of California residents that is collected both in the business-to-business and employment contexts. Numerous other state-specific privacy laws also take effect in 2023, including in Colorado, Connecticut and Virginia, with laws in additional states to go into effect next year. There continues to be a flurry of state-level activity in the privacy space in the absence of a federal privacy or data breach notification law in the U.S. At the federal level, the FTC continues to be laser-focused on companies' data collection and sharing practices, with a particular focus on health information, biometric information and risks related to the use of AI. The Securities and Exchange Commission also remains active in the cyber space, proposing onerous data breach and cyber risk management requirements, including a proposed rule that would require registrants to provide periodic disclosures about policies and procedures for managing cybersecurity risks and cybersecurity incident reporting. The surge of activity at both the federal and state levels comes against the backdrop of an increase in ransom/cyber extortion and vendor/supply chain incidents. This has created a complex environment for PE buyers who need to gauge privacy risks associated with the data-driven companies they seek to acquire and with targets who are looking to present robust privacy and cybersecurity compliance programs.

In January 2023, the FTC issued a Notice of Proposed Rulemaking that would effectively prohibit the use of employee non-competition covenants in all but very limited circumstances. Specifically, if enacted (and not struck down by legal challenge), the rule would make it unlawful for an employer to enter into, or attempt to enter into, a non-compete agreement with any "worker," including any employee or independent contractor. The rule would also prohibit use of other types of contractual provisions, such as customer non-solicitation covenants, that have the effect of prohibiting a worker from seeking or accepting employment with an employer following the termination of employment. The proposed rule does not distinguish among types of employees and contains only a limited exception for individual sellers of a business who are "substantial" owners, members or partners in the business. The rule as drafted also

applies retroactively and requires the affirmative rescission of existing non-competition agreements that violate the rule. The comment period with respect to the proposed rule is now closed and the FTC has yet to announce whether it intends to proceed with issuing the rule as originally drafted. Following its issuance, the rule is likely to be subject to numerous legal challenges. In addition, legislation by states restricting non-competes has also been on the rise. Most recently, the New York State Legislature passed a bill banning virtually all new employee non-competes. The bill was passed on June 7, 2023 by the New York State Senate, and on June 20, 2023 by the New York State Assembly. As of this writing, the New York state legislature is considering whether any changes should be made to the bill before it is sent to the Governor for review. Note that, by contrast with California's state-wide ban on non-competes and the FTC's proposed nationwide ban, the New York law as currently drafted does not contain any exceptions for sellers of businesses.

The U.S. government is considering implementing an outbound investment review mechanism that will likely focus on investments made from the United States in certain sectors of the Chinese economy. Measures currently under consideration would require notification by U.S. persons investing in targeted sectors; however, the initial measures are unlikely to require pre-clearance by the U.S. government for covered investments. The specific requirements and timing of the outbound investment reviews will be of great interest for U.S. investors over the coming months. See question 4.1.

In June 2023, the FTC announced proposed rules that would significantly increase the amount of information that parties to acquisition transactions need to include in their HSR filings. If implemented, these proposed rules would likely to increase the amount of time parties spend preparing for, and the FTC's review of, HSR filings. As a result, the proposed new rules could increase the interim period between signing and closing for applicable transactions. See question 4.1.

In July 2023, the DOJ and FTC announced draft new Merger Guidelines, which are intended to increase merger enforcement of entities that engage in patterns or series of acquisitions that may be anticompetitive. See question 4.1.

### 11.2 Are private equity investors or particular transactions subject to enhanced regulatory scrutiny in your jurisdiction (e.g., on national security grounds)?

There is enhanced scrutiny by CFIUS of transactions involving non-U.S. investors and U.S. businesses that operate in industries, or otherwise deal with technologies or personal data, that are deemed to be sensitive from a national security perspective. Transactions involving Chinese investors, in particular, continue to be subject to intense scrutiny by CFIUS. In addition, FIRRMA expanded CFIUS's jurisdiction to enable review not only of investments in which non-U.S. investors might be acquiring control over U.S. businesses (which have always been subject to CFIUS review), but also certain investments in which non-U.S. persons would gain certain rights involving appointment of directors, access to material non-public technical information, or other substantive decision-making board appointment rights even in the absence of control. Investments by non-U.S. entities that are partially or wholly owned by non-U.S. governments also are subject to heightened scrutiny and might trigger mandatory filing requirements. There are exceptions, however, for certain PE investments made through partnerships in which the general partner is a U.S. entity or is domiciled in an "excepted state" (which currently includes Australia, Canada, and the United Kingdom).

In addition, the FTC and DOJ have increased their review of PE transactions. See question 11.1.

### 11.3 Are impact investments subject to any additional legal or regulatory requirements?

Impact investing and impact funds are on the rise. Impact investing involves allocating funds to assets that generate positive societal or environmental impact combined with financial returns. These investments, which can be made in both emerging and developed markets, attempt to solve unheeded societal and environmental challenges (rather than merely avoid harm, as with socially responsible investing). While the particulars differ, impact investment firms are generally still profit-seeking entities, requiring at least a return on invested capital and some additional disclosures related to its non-financial metrics. This type of investing differs from ESG, because impact is a strategy concerned with the types of investments a manager targets while ESG is focused on how individual companies interact with the world.

Whether a manager of an impact investment firm is subject to a different fiduciary standard when making an impact investment depends on what type of firm makes the investment. For example, a qualified pension plan trustee could not use pension funds for “impact investments” if there was evidence that such an investment would not have a positive return, and if the trustee pursued this investment against the evidence, the trustee would be abdicating his fiduciary responsibility to seek the maximum financial return for the plan’s beneficiaries. In contrast, a charity manager could consider a particular investment’s special relationship with the institution’s charitable purposes. If an investment sacrifices financial return to further a non-financial purpose, the non-financial objectives and the non-financial factors considered must directly relate to the charitable purposes of the organization making the investment and disclosure should be made regarding the same. Large asset managers who are creating impact investing funds will want to ensure that the particular investments pursued align with the stated mission and impact objectives marketed to LPs and that their investment committee is informed throughout the diligence and deal selection process.

### 11.4 How detailed is the legal due diligence (including compliance) conducted by private equity investors prior to any acquisitions (e.g., typical timeframes, materiality, scope, etc.)?

The scope, timing and depth of legal due diligence conducted by PE sponsors in connection with acquisitions depends on, among other things, the transaction size, the availability of public information, the nature and complexity of the target’s business and the overall transaction timeline. Sponsors may conduct certain diligence in-house, but outside counsel typically handles the bulk of legal diligence. Specialized advisers may be retained to conduct diligence in areas that require particular expertise. PE sponsors have been increasing their focus on due diligence regarding ESG and data security.

### 11.5 Has anti-bribery or anti-corruption legislation impacted private equity investment and/or investors’ approach to private equity transactions (e.g., diligence, contractual protection, etc.)?

PE buyers and counsel will evaluate the target’s risk profile with respect to anti-bribery and anti-corruption legislation,

including the Foreign Corrupt Practices Act (“FCPA”). The risk profile depends on, among other things, whether the target conducts foreign business and, if so, whether any of the business is conducted (i) in high-risk regions (e.g., China, India, Venezuela, Russia and other former Soviet countries and the Middle East), (ii) with foreign government customers, or (iii) in industries with increased risk for violations (e.g., defense, aerospace, energy and healthcare). Diligence will be conducted based on the risk profile and possible violations identified need to be thoroughly evaluated and potentially self-reported to the relevant enforcement authorities. In particular, the imposition of numerous sanctions and export controls against Russia in 2022 and 2023 has led to intense scrutiny of a target’s operations in, or connection to, Russia, to identify potential violations or impacts on revenue derived from Russia, among other issues.

The DOJ may impose successor liability and sanctions on PE buyers for a target’s pre-closing FCPA violations. PE buyers typically obtain broad contractual representations from sellers regarding anti-bribery and anti-corruption matters and often insist on compliance enhancements to be implemented as a condition of investment.

### 11.6 Are there any circumstances in which: (i) a private equity investor may be held liable for the liabilities of the underlying portfolio companies (including due to breach of applicable laws by the portfolio companies); and (ii) one portfolio company may be held liable for the liabilities of another portfolio company?

Fundamentally, under U.S. law, businesses operated as legally recognized entities are separate and distinct from owners. Consequently, PE sponsors generally will not be liable for acts of portfolio companies. However, there are several theories under which “corporate” form will be disregarded. These include:

- (i) Contractual liability arising to the extent the PE sponsor has agreed to guarantee or support the portfolio company.
- (ii) Common law liability relating to: (a) veil piercing, alter ego and similar theories; (b) agency and breach of fiduciary duty; and (c) insolvency-related theories. Most often, this occurs when the corporate form has been misused to accomplish certain wrongful purposes or a court looks to achieve a certain equitable result under egregious circumstances.
- (iii) Statutory control group liability relating to securities, employee benefit and labor laws, the FCPA and consolidated group rules under tax laws.

The two most common areas of concern relate to potential liabilities under U.S. environmental laws and employee benefit laws. The Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) can impose strict liability on owners and/or operators of a facility with respect to releases of hazardous substances at the facility owned or operated by the portfolio company. However, unless PE sponsors exercise actual and pervasive control of a portfolio company’s facility by involving themselves in the portfolio company’s daily operations at the facility or its environmental activities, they should not be exposed to liability as an operator of such facility. Parents also should not have indirect or derivative liability for the portfolio company’s liability under CERCLA, unless there is a basis for veil piercing.

Under the Employee Retirement Income Security Act (“ERISA”), if an entity sponsors a qualified defined benefit pension plan or participates in a multiemployer defined benefit pension plan (typically as part of a collective bargaining agreement with a union), that entity and all other entities in the same “controlled group” are jointly and severally liable for the entity’s pension obligations (such as funding and withdrawal liability

obligations). A “controlled group” generally consists of a group of trades or businesses under common control, which generally requires at least 80% direct or indirect common ownership (measured by vote or value as to all classes of an entity’s equity) between or among the entities involved. Historically, PE funds have not been considered to be engaged in a “trade or business” (and thus would not be part of the same controlled group as their respective portfolio companies), but in light of recent case law developments, there is now some uncertainty whether such treatment can be assured. Recent case law has applied a facts-intensive “investment plus” analysis to hold that a PE fund sponsor that had active involvement and broad authority in the management of a portfolio company was engaged in a “trade or business” for purposes of testing controlled group status. Consequently, if a court were to find that a PE fund sponsor was engaged in a “trade or business” based on the reasoning applied in the referenced case law and if such PE fund sponsor also had sufficient common ownership with a portfolio company group such that the PE fund sponsor was found to be a member of the same controlled group as that portfolio company group, the PE fund sponsor could be jointly and severally liable for the defined benefit pension liabilities of that portfolio company group. Moreover, it could logically follow that the court could then find that other portfolio company groups owned by the same PE fund sponsor could also be jointly and severally liable for the defined benefit pension liabilities of the first portfolio company group if the 80% common ownership thresholds were satisfied. PE fund sponsors should carefully consider how to structure their investments in portfolio companies with qualified defined benefit pension obligations and consult with knowledgeable legal counsel to attempt to minimize the controlled group liability exposure presented by the foregoing principles.

## 12 Other Useful Facts

**12.1 What other factors commonly give rise to concerns for private equity investors in your jurisdiction or should such investors otherwise be aware of in considering an investment in your jurisdiction?**

Contract law in the United States embraces the freedom to contract. Absent public policy limits, PE sponsors in U.S.

transactions are generally able to negotiate and agree upon a wide variety of transaction terms in acquisition documents that satisfy their underlying goals.

Transaction parties should expect increased regulation in the United States. In particular, new regulations should be expected in the arenas of cybersecurity and protection of personal data (both at the federal and state level) that will affect both how diligence is conducted and how portfolio companies operate. See question 11.1. Tax continues to be a key value driver in PE transactions, with IRRs and potential risks depending on tax considerations. See section 10.

Increased attention must be paid to potential CFIUS concerns, particularly given recent reforms and the political climate. Non-U.S. PE investors should be aware that investing in a U.S. business might trigger mandatory filing requirements. Even if a filing is not mandatory, it nonetheless may be advisable to submit a voluntary filing in order to avoid deal uncertainty, as CFIUS has the ability to open a review even after closing has occurred and could even require divestment. CFIUS considerations will remain a key issue for PE sponsors in 2023. See section 11.

PE investors also need to be aware of the FTC’s and individual states’ increased focus on employee non-competition covenants when negotiating employment arrangements with management. They should ensure that any such covenants are drafted narrowly so that they protect the legitimate business interests of the company and are reasonable with respect to duration, geographic reach and scope of restricted activities. See section 11.

## Acknowledgments

The authors would like to thank **Joshua Milgrim**, a tax partner at Dechert LLP, **James Fishkin**, an antitrust partner at Dechert LLP, **Abbi Cohen**, a corporate and securities partner at Dechert LLP who focuses her practice on environmental matters, **Ian Downes**, a labor and employment partner at Dechert LLP, **Darshak Dholokia**, an international trade partner at Dechert LLP, **Hilary Bonaccorsi**, a data privacy and cybersecurity associate at Dechert LLP, **Sarah Burke**, an employee benefits and executive compensation associate at Dechert LLP, and **Daniel Rubin**, a professional support lawyer at Dechert LLP, for their contributions to this chapter.



**Allie Misner Wasserman** focuses her practice on corporate and securities matters. Ms. Wasserman represents PE sponsors and their portfolio companies as well as strategic buyers and sellers in M&A transactions across a wide range of industry sectors. Her clients include Court Square Capital Partners, One Equity Partners and Morgan Stanley Capital Partners. Ms. Wasserman was recently recognized for her transactional expertise by *The Deal* in its Top Rising Stars: Class of 2021 list.

**Dechert LLP**  
Cira Centre, 2929 Arch Street  
Philadelphia, PA 19104–2808  
USA

Tel: +1 215 994 2449  
Email: [allie.wasserman@dechert.com](mailto:allie.wasserman@dechert.com)  
URL: [www.dechert.com](http://www.dechert.com)



**Dr. Markus P. Bolsinger, LL.M.**, co-head of Dechert's PE practice, structures and negotiates complex transactions – domestic and transatlantic M&A, leveraged buyouts, recapitalizations and going-private transactions – and advises on general corporate and corporate governance matters. Dr. Bolsinger's experience extends across industries, including healthcare, technology, industrial, agribusiness, consumer, food and beverage, and restaurant sectors. His clients include leading PE firms, such as ArchiMed, First Atlantic Capital, ICV Partners, J.H. Whitney & Co., Morgan Stanley Capital Partners and Ridgemont Equity Partners. In addition to his core M&A and PE experience, Dr. Bolsinger has extensive expertise in transactional risk insurance.

He has been listed as a recommended lawyer by the U.S., EMEA and Germany editions of *The Legal 500*, a legal directory based on the opinions of clients and peers. Recognized for M&A and PE buyouts, Dr. Bolsinger has been cited as being a "business-oriented advisor and highly effective manager of complex processes". Since 2010, Dr. Bolsinger has been recognized and received a *pro bono* service award every year.

**Dechert LLP**  
Three Bryant Park, 1095 Avenue of the Americas  
New York, NY 10036-6797, USA /  
Skygarden, Erika-Mann-Straße 5  
Munich 80636, Germany

Tel: +1 212 698 3628 / +49 89 2121 6309  
Email: [markus.bolsinger@dechert.com](mailto:markus.bolsinger@dechert.com)  
URL: [www.dechert.com](http://www.dechert.com)



**Soo-ah Nah** is a partner in Dechert's global finance practice with a focus on leveraged finance. Ms. Nah represents PE sponsors and their portfolio companies, as well as other public and private companies across industries and institutional lenders, on acquisition financings and various other types of financing transactions. She also provides general corporate and financial advice to her clients. Ms. Nah was recently included in *Kayo Conference Series'* Top 22 in 22 women leaders in leveraged finance. She is also recognized for her work in commercial lending by *The Legal 500 (US)*.

**Dechert LLP**  
Three Bryant Park, 1095 Avenue of the Americas  
New York, NY 10036-6797  
USA

Tel: +1 212 698 3550  
Email: [sooah.nah@dechert.com](mailto:sooah.nah@dechert.com)  
URL: [www.dechert.com](http://www.dechert.com)



**Marie Mast** focuses her practice on corporate and securities matters, with a particular emphasis on M&A, capital markets and general corporate matters.

Ms. Mast advises PE firms and strategic companies on transactions across a wide range of industries, including healthcare, food and beverage, education and life sciences.

**Dechert LLP**  
Cira Centre, 2929 Arch Street  
Philadelphia, PA 19104–2808  
USA

Tel: +1 212 994 2172  
Email: [marie.mast@dechert.com](mailto:marie.mast@dechert.com)  
URL: [www.dechert.com](http://www.dechert.com)

Dechert has been at the forefront of advising PE firms for almost 40 years. With more than 300 PE and private investment clients, we have unique insights into how the industry has evolved and where it is going next. Our globally integrated team of more than 350 PE lawyers advises PE, private credit and other alternative asset managers on flexible solutions at every phase of the investment life cycle.

[www.dechert.com](http://www.dechert.com)

Dechert  
LLP

# Invested in your SUCCESS

Dechert advises private equity, private credit and other alternative asset managers on capital solutions at every phase of the investment life cycle. We form funds, negotiate investments, advise on transactions and financings that maximise value, and structure and execute exits accomplished at the right time to deliver the best returns. With lawyers in the United States, Europe, Asia and the Middle East, our interdisciplinary global team has the reach, resources and expertise to advise our clients wherever they do business.

**Top ranked for U.S. and Global PE Buyouts by *Mergermarket*, and Global M&A by *Bloomberg* and *Refinitiv***

**Committed  
Capital**

A GLOBAL PRIVATE EQUITY PODCAST

**Listen and subscribe to our podcast.**

Hosted by members of Dechert's private equity practice, Committed Capital explores current issues and trends affecting PE globally, featuring conversations with leaders from across the industry. [dechert.com/private\\_equity](https://dechert.com/private_equity)



**Dechert**  
LLP

Austin ▪ Beijing ▪ Boston ▪ Brussels ▪ Charlotte ▪ Chicago ▪ Dubai ▪ Dublin ▪ Frankfurt ▪ Hong Kong  
London ▪ Los Angeles ▪ Luxembourg ▪ Munich ▪ New York ▪ Paris ▪ Philadelphia  
San Francisco ▪ Silicon Valley ▪ Singapore ▪ Washington, D.C.

Dechert  
LLP

---

**PRIVATE EQUITY**  
INVESTED IN YOUR SUCCESS SINCE 1984

[dechert.com](http://dechert.com)